Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers life-changing therapies to people living with rare disease.

Metric
Company Name	Travere Therapeutics, Inc.	Sarepta Therapeutics, Inc.
Symbol	TVTX	SRPT
MSH ID	COM:TRAVERE	COM:SAREPTA
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	380	1.31K
Website	travere.com	sarepta.com
LinkedIn
Founders

Metric
Market Cap	725.51M	14.11B
Enterprise Value
Monthly Web Traffic		12.98K
Web Traffic Growth		-0.26
Valuation
Raised Capital		5.96M

Metric
Revenue	145.24M	1.24B
Revenue (LTM)
Revenue (NTM)
Gross Profit	88.86M	1.09B
EBITDA	-331.81M	-267.82M
Operating Income	-376.74M	-267.82M
Net Income	-111.40M	-535.98M
EPS	-1.50	-5.80
Diluted EPS	-1.50	-5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.89	0.88
Operating Profit Margin	-1.71	0.03
EBITDA Margin	-2.28	-0.22
Net Profit Margin	-0.56	0.03
Return on Equity	-0.57	0.05
Return on Assets	-0.14	0.01
Return on Capital Employed	-0.56	0.01

COM:TRAVERE

Travere Therapeutics

Last Close

23.72

14/02 21:00

Market Cap

725.51M

Beta: -

Volume Today

1.25M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-7.24	-16.13
P/B Ratio	2.25	14.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.86	11.03
EV Multiple	-0.28	207.35

Metric
Days Sales Outstanding	25.37	117.02
Days Payables Outstanding	891.10	234.37
Days Inventory Outstanding	138.38	958.33
Operating Cycle	177.26	1.05K
Cash Conversion Cycle	-164.65	841.56
Asset Turnover	0.32	0.44

Metric
Operating Cash Flow	-280.02M	-500.99M
Free Cash Flow	-322.28M	-588.34M
Cash Flow to Debt	-0.73	-0.32
Operating Cash Flow/Sales	-1.41	-0.26
Free Cash Flow Yield	-0.13	-0.05

Metric
Cash & Equivalents	58.18M	428.43M
Accounts Receivable	-11.26M	-185.70M
Inventory	9.41M	322.86M
Goodwill	800K
Debt to Capitalization	0.96	0.59
Debt to Assets	0.49	0.54
Current Ratio	4.92	5.44
Quick Ratio	3.31	3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.22	0.17
R&D to Revenue	1.19	0.81
SG&A to Revenue	0.62	0.43